RESUMO
No disponible
Assuntos
Feminino , Criança , Humanos , Pitiríase Liquenoide/diagnóstico , Pitiríase Liquenoide/tratamento farmacológico , Hiperpigmentação/complicações , Hiperceratose Epidermolítica/diagnóstico , Eritromicina/uso terapêutico , Terapia PUVA , Prednisona/uso terapêutico , Minociclina/uso terapêutico , Tetraciclinas/uso terapêutico , Metotrexato/uso terapêutico , Eritema/complicações , Hipersensibilidade/complicações , Pitiríase Liquenoide/complicações , Hiperpigmentação/diagnóstico , Hiperceratose Epidermolítica/complicações , Hipersensibilidade/diagnóstico , Diagnóstico Diferencial , Dermatite de Contato/complicações , Técnica Direta de Fluorescência para Anticorpo/métodos , Dermatopatias/complicaçõesRESUMO
We have analyzed retrospectively fifty conjunctival samples from infants less than one month of age affected with conjunctivitis. Of these samples, 84% had a positive bacterial culture, with the microorganisms isolated, in order of frequency, being: Staphylococcus epidermidis (14%), Staphylococcus aureus (14%), Streptococcus pneumoniae (12%), Haemophilus sp, Chlamydia and alpha-hemolytic Streptococcus (8%). All of these showed a high sensitivity to most of the drugs tested, except to penicillin and its derivatives. Cefotaxime, ceftriaxone and ciprofloxacin showed the highest in vitro activities. Of the pharmacological ophthalmic preparations commercially available in our country, sulfonamides, chloramphenicol, rifampicin, erythromycin and tobramycin are the agents more active against the bacteria described above.
Assuntos
Antibacterianos/uso terapêutico , Conjuntivite Bacteriana/tratamento farmacológico , Conjuntivite Bacteriana/microbiologia , Doença Aguda , Antibacterianos/farmacologia , Feminino , Humanos , Recém-Nascido , Masculino , Testes de Sensibilidade Microbiana , Estudos RetrospectivosRESUMO
Patients cured from endogenous Cushing syndrome usually develop postoperative adrenal suppression in the year ensuing surgery. To define whether the pituitary corticotroph is the rate limiting step in the postoperative recovery of this secondary/tertiary form of adrenal insufficiency, we examined surgically cured patients with Cushing syndrome 10 days, 3 months, and 6-12 months after surgery, by administering ovine CRH (oCRH) iv at the dose of 1 microgram/kg.h over 24 h. The pituitary corticotroph of these patients responded vigorously to oCRH, with ACTH concentrations reaching above the normal range at all three times of testing. Parallel measurements of cortisol in nonadrenalectomized patients demonstrated subnormal adrenal responsiveness at 10 days and 3 months and normalization at 6-12 months after surgery. The circadian rhythm of ACTH was maintained postoperatively at 10 days and 6-12 months, and the circadian rhythm of cortisol was also present at 6-12 months after surgery, in spite of the constant infusions of pharmacological doses of oCRH, suggesting that factors other than CRH secretion regulate this rhythm. We conclude that the corticotroph is not the rate limiting step in the recovery of the hypothalamic-pituitary-adrenal axis from glucocorticoid-induced adrenal suppression, and that the locus of the defect resides in the hypothalamic CRH neuron and/or its higher regulatory inputs.
Assuntos
Glândulas Suprarrenais/fisiopatologia , Hormônio Adrenocorticotrópico/metabolismo , Síndrome de Cushing/cirurgia , Hipotálamo/fisiopatologia , Hipófise/fisiopatologia , Adolescente , Adulto , Criança , Ritmo Circadiano , Hormônio Liberador da Corticotropina , Síndrome de Cushing/fisiopatologia , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Período Pós-OperatórioRESUMO
We studied the effects of tumor necrosis factor-alpha (TNF alpha), a macrophage-derived pleiotropic cytokine produced during the inflammatory/immune response, on the function of the hypothalamic-pituitary-adrenal (HPA) axis of the rat. Intravenous injections of TNF alpha stimulated plasma ACTH and corticosterone secretion in a dose-dependent fashion. This effect was inhibited by a rat CRH antiserum that was administered to the rats 1 h before the TNF alpha injections. This suggested that CRH is a major mediator of the HPA axis response to TNF alpha. We subsequently evaluated the ability of TNF alpha to influence CRH and ACTH secretion in vitro by explanted rat hypothalami in organ culture and by dispersed rat anterior pituicytes in primary culture respectively. Hypothalami were incubated for 40 min with graded concentrations of TNF alpha (10 pM to 1 microM). This cytokine stimulated CRH secretion in a dose-dependent fashion, with an EC50 of 6.7 x 10 pM (P less than 0.05). Preincubation of hypothalamic explants with dexamethasone, indomethacin (1 microM), eicosatetraynoic acid (10 microM), or nordihydroguaiaretic acid (30 microM) resulted in inhibition of TNF alpha-stimulated CRH secretion (P less than 0.05). Interestingly, 4-h incubation with TNF alpha had no effect on ACTH secretion from rat anterior pituicytes at a concentration of 10 nM. Higher concentrations of TNF alpha (100 nM and 1 microM), however, elicited a dose-dependent increase in the ACTH concentration in the medium. Our results suggest that TNF alpha represents one of the immune response mediators that directly or via stimulation of other cytokines act as activators of the HPA axis during immune/inflammatory reactions. This effect appears to be glucocorticoid suppressible and eicosanoid mediated. The primary site of action of TNF alpha appears to by the hypothalamic CRH-secreting neuron. Some pituitary and adrenal effects of TNF alpha, however, cannot be excluded.
Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Hormônio Liberador da Corticotropina/fisiologia , Fator de Necrose Tumoral alfa/farmacologia , Ácido 5,8,11,14-Eicosatetrainoico/farmacologia , Animais , Células Cultivadas , Corticosterona/metabolismo , Hormônio Liberador da Corticotropina/imunologia , Dexametasona/farmacologia , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Soros Imunes/farmacologia , Indometacina/farmacologia , Injeções Intravenosas , Cinética , Masculino , Masoprocol/farmacologia , Hipófise/efeitos dos fármacos , Hipófise/metabolismo , Ratos , Ratos Endogâmicos , Fator de Necrose Tumoral alfa/administração & dosagemRESUMO
Several lines of experimental evidence suggest that acetylcholine and other cholinergic agonists are excitatory to the hypothalamic-pituitary-adrenal (HPA) axis. To examine the site on the HPA axis that is stimulated by cholinergic agents, we evaluated the in vivo and in vitro effects of the muscarinic cholinergic agonist arecoline in intact and pituitary stalk-transected rats as well as on isolated rat hypothalami, dispersed anterior pituicytes, and adrenocortical cells in culture. Arecoline, injected iv to catheterized, freely moving male Sprague-Dawley rats, stimulated plasma ACTH and corticosterone release in a dose-dependent fashion. The muscarinic cholinergic antagonist atropine significantly blunted the ACTH response to arecoline. Pituitary stalk transection led to diminished plasma ACTH and corticosterone responses to arecoline. Similarly, previous administration of anti-CRH serum significantly blunted these responses. These findings suggest that arecoline stimulates the HPA axis centrally, mainly via secretion of CRH. This hypothesis was confirmed by the dose-dependent ability of arecoline to cause hypothalamic CRH secretion in vitro, an effect antagonized by atropine, and its failure to elicit ACTH and corticosterone secretion by dispersed anterior pituicytes and adrenocortical cells in culture, respectively. These data suggest that the muscarinic cholinergic agonist arecoline stimulates the HPA axis in the rat and that this effect is mediated mainly by the release of endogenous CRH. Arecoline, therefore, appears to be a compound suitable to selectively evaluate the responsiveness of the central component of the HPA axis.